TY  - JOUR
AU  - Tomsitz, Dirk
AU  - Livingstone, Elisabeth
AU  - Loquai, Carmen
AU  - Kaatz, Martin
AU  - Leiter, Ulrike
AU  - Schilling, Bastian
AU  - Terheyden, Patrick
AU  - Hassel, Jessica
AU  - Sachse, Michael
AU  - Ulrich, Jens
AU  - Dippel, Edgar
AU  - Meiss, Frank
AU  - Pföhler, Claudia
AU  - Kreuter, Alexander
AU  - Herbst, Rudolf
AU  - Weichenthal, Michael
AU  - Zimmer, Lisa
AU  - Meier, Friedegund
AU  - Rauschenberg, Ricarda
AU  - Mohr, Peter
AU  - Brunnert, Fiona
AU  - von Wasielewski, Imke
AU  - Gutzmer, Ralf
AU  - Schadendorf, Dirk
AU  - Berking, Carola
AU  - Ugurel, Selma
AU  - Heinzerling, Lucie
TI  - Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 39
IS  - 11
SN  - 0926-9959
CY  - Oxford [u.a.]
PB  - Wiley-Blackwell
M1  - DKFZ-2025-00603
SP  - 1975-1986
PY  - 2025
N1  - 2025 Nov;39(11):1975-1986
AB  - Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti-PD1 therapy.From the prospective multicentre real-world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 ± 4 weeks; n = 229) and no disease recurrence during therapy (A1) and patients with a premature end of treatment (<48 weeks; n = 214, B). Patients with disease recurrence during adjuvant treatment were included in cohort A2.The median duration of follow-up was 26.0 months [interquartile range (IQR) 18.0-34.0] in group A1 [median treatment duration 51.3 weeks (IQR 50.0-52.1) and 19.0 months (IQR 13.0-29.0)] in group B [median treatment duration 22.2 weeks (IQR 10.0-34.8)]. Reasons for early discontinuation were treatment-related side effects in 45.3
LB  - PUB:(DE-HGF)16
C6  - pmid:40119686
DO  - DOI:10.1111/jdv.20650
UR  - https://inrepo02.dkfz.de/record/300103
ER  -